Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · RELMADA THERAPEUTICS, INC. (RLMD)

Relmada Therapeutics Q2 net loss widens to $12.9 million; cash rises to $217.7 million

Mixed Impact 3 of 5 earnings Written later

Relmada reported a second-quarter 2026 net loss of $12.9 million, up from $9.9 million a year earlier, as research and development spending rose to $8.4 million from $2.8 million. The loss per share narrowed to $0.11 from $0.30, but the company's weighted average share count grew to 112.4 million from 33.2 million. The company said its $217.7 million in cash and short-term investments is expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program.

Key points

  • Net loss of $12.9 million, or $0.11 per share, for the three months ended June 30, 2026, versus $9.9 million, or $0.30 per share, a year earlier
  • Research and development expense rose to $8.4 million from $2.8 million, mainly due to higher NDV-01 and sepranolone study costs and manufacturing and drug storage costs
  • Cash, cash equivalents and short-term investments were $217.7 million at June 30, 2026, up from about $93.0 million at December 31, 2025
  • The company expects to submit the NDV-01 IND and the sepranolone IND by year-end 2026

The filing

CompanyRELMADA THERAPEUTICS, INC. (RLMD)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:40 PM ET
Accession number0001213900-26-086190

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.